Mark Glickman

Mr. Mark A. Glickman is an Independent Director at BioStem Technologies, Inc., a President & Chief Executive Officer at BioFlorida, Inc. and an Independent Director at MetaVia, Inc. He is on the Board of Directors at BioStem Technologies, Inc., Otsuka Precision Health, Inc. and MetaVia, Inc. Mr. Glickman was previously employed as a Co-CEO & Chief Business Officer by TherapeuticsMD, Inc., a Chief Commercial Officer by Esperion Therapeutics, Inc., a Chief Commercial Officer by POZEN, Inc., a Chief Commercial Officer by Aralez Pharmaceuticals, Inc., a Senior Vice President-Sales by Auxilium Pharmaceuticals LLC, a Vice President-Medical Device Division by Otsuka America Pharmaceutical, Inc., a Senior Vice President-Sales & Marketing by Oscient Pharmaceuticals Corp., a Marketing Director & Vice President-Sales by KOS Pharmaceuticals, Inc., a General Manager-Sales by Baxter Healthcare Corp., and a Vice President-Sales by Bayer HealthCare /Diabetes Care Division/.
He received his undergraduate degree from State University of New York College at Oswego and an MBA from Nyu Stern School of Business.